Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: A multicenter phase II study of the Hellenic Oncology Research Group

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1687-1692

  Boukovinas, I ^a   Androulakis, N ^b   Vamvakas, L ^b   Papakotoulas, P ^a   Ziras, N ^c   Polyzos, A ^d   Kalykaki, A ^b   Kotsakis, A ^b   Xenidis, N ^a   Gioulmbasanis, I ^b   Mavroudis, D ^b   Georgoulias, V ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bladder cancer; Cisplatin; Docetaxel; Gemcitabine; Transitional cell carcinoma

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; GREECE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; TAXOIDS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 33750585961     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl286     Document Type: Article

References (31)

1. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
2. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicine and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
3. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
4. Raghavan D, Shipley WU, Garnick MB et al. The biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-1138.
5. Igawa M, Ohkuchi T, Ueki T et al. Usefulness and limitations for methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990; 144: 662-665.
6. Geller NL, Sternberg CN, Penenberg D et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991; 67: 1525-1531.
7. Von der Masse H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicentre, phase III study. J Clin Oncol 2000; 18: 3068-3077.
8. Vaughn DJ. Review and outlook for the role of paclitaxel in urothelial carcinoma. Semin Oncol 1999; 26 (Suppl 2): 117-122.
9. Von der Masse H, Sengelov L, Roberts JT et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
10. Culine S. The present and future of combination chemotherapy in bladder cancer. Semin Oncol 2002; 29 (3 Suppl 9): 32-39.
11. Hussain M, Vaishampayan U, Wei D et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-2533.
12. Bajorin DF, McCafferty JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Final report of a phase II trial evaluating two dosing schedules. Cancer 2000; 88: 1671-1678.
13. Bellmunt J, Guillem V, Pax-Ares L et al. Phase I-II study of paclitaxel. Cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Genitourinary Group. J Clin Oncol 2000; 18: 3247-3255.
14. Bajorin DF, McCafferty JA, Hilton S et al. Treatment of patients with transitionalcell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial. J Clin Oncol 1998; 16: 2722-2727.
15. Hussain M, Vaishampayan U, Smith DC. Novel gemcitabine-containing triplets in the management of urothelial cancer. Semin Oncol 2002; 29: 20-24.
16. Pectasides D, Glotsos J, Bountouroglou N et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: A phase II trial. Ann Oncol 2002; 13: 243-250.
17. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853-1857.
18. de Wit R, Kruit WH, Stoter G et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer: Results of a phase II study in non-chemotherapypretreated patients. Br J Cancer 1998; 78: 1342-1345.
19. Sengelov L, Kamby C, Lund B et al. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study. J Clin Oncol 1998; 16: 3392-3397.
20. Dimopoulos MA, Bakoyannis C, Georgoulias et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 1385-1388.
21. Garcia del Muro X, Marcuello E, Guma J et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002; 86: 326-330.
22. Edelman MJ. New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep 2000; 2: 379-385.
23. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181.
24. Kaufman D, Raghavan D, Carduui M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921-1927.
25. DiPaola RS, Rubin E, Toppmeyer D et al. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit 3002; 9: 5-11.
26. Norton L, Day RS. Potential innovations in scheduling in cancer chemotherapy. In De Vita Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA: Lippincott-Raven Publishers 1991; 57.
27. Bonnadonna G, Zambetti M. Sequential or alternating doxorubicin and CMF regimen in breast cancer with more than three positive nodes. JAMA 1995; 273: 542.
28. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876-2881.
29. Von der Maase H, Anderson L, Crino L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999; 10: 1461-1465.
30. Frassoldati A, Bisagni G, Passalacqua R et al. Gemcitabine, cisplatin and paclitaxel (GPT) in advanced transitional bladder cancer. Is there a scheduledependent clinical effect? Proc Am Soc Clin Oncol 2000; 19: 366a (Abstr 1449).
31. Sledge G, Neuberg D, Berarrdo P et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003; 21: 588.